MPM BioImpact’s Akebia Therapeutics AKBA Stock Holding History

MPM BioImpact’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,889,125	Closed	-$7.89M	–	39
2025 Q3	$7.89M	Hold	2,889,125	–	–	1.29%	30
2025 Q2	$10.5M	Buy	+2,889,125	New	+$7.94M	1.82%	23

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MPM BioImpact's AKBA Position: Q4 2025 in Review

MPM BioImpact sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 2,889,125 shares — an estimated $7.89M sold.

MPM BioImpact first reported a position in AKBA in Q2 2025 and held it in 2 quarters. The position peaked at $10.5M in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

MPM BioImpact reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
MPM BioImpact sold 2,889,125 Akebia Therapeutics shares in Q4 2025, an estimated $7.89M.
MPM BioImpact first reported a position in Akebia Therapeutics in Q2 2025 and held it in 2 quarters.
MPM BioImpact's Akebia Therapeutics position peaked at $10.5M in Q2 2025.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.